Weekly round-up: The appointment of a new CEO to Phase 1 data from a novel GLP-1 receptor agonist…
Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for regenerating bone and managing infection in bone and soft tissue, on Thursday announced that it will begin distributing its NanoBone range of products in the UK.
The range consists of NanoBone SBX Putty and NanoBone QD, which are next generation synthetic bone grafts that provide reliable early osteogenesis and bone formation.
QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024
Beijing QL Biopharmaceutical Co., Ltd., a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, on Thursday announced that Phase 1c clinical data for its lead drug candidate ZT002 was presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, in Madrid, Spain.
ZT002 is a novel, ultra long-acting, glucagon-like peptide-1 receptor agonist (GLP-1RA) in development for obesity with monthly subcutaneous administration.
Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer
Alchemab Therapeutics, a pharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, on Thursday announced that Jane Osbourn, OBE, FMEDSCI, PhD, Alchemab’s Co-Founder and Chief Scientific Officer (CSO), was appointed as Chief Executive Officer (CEO) and member of the Board.
Jane has led all aspects of Alchemab’s platform development and drug discovery activities to date and brings more than 30 years of biopharmaceutical industry experience to the CEO role.
Sofinnova Partners appoints Karl Naegler as Partner
Sofinnova, a leading European venture capital firm in life sciences, on Tuesday announced the appointment of Karl Naegler as Partner. This strategic hire also marks Sofinnova’s expansion into Germany, bolstering its reach and influence across Europe.
A seasoned investor with 20 years of experience and a strong track record, Naegler enhances the VC’s well-established team of partners, strengthening the firm’s early-stage investment strategy.
Pheon Therapeutics Expands Board with Appointment of Dr. Enoch Kariuki
Pheon Therapeutics, a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, on Tuesday announced the appointment of accomplished biotech executive, Enoch Kariuki, Pharm.D., to its Board of Directors as an independent, non-executive director.
Dr. Kariuki brings a wealth of experience in ADCs, across corporate strategy, finance and operations as Pheon advances its differentiated pipeline and accelerates its first program, PHN-010, into clinical development this year.
Catch up on the latest life sciences sector moves
Check out the latest moves in the life sciences sector with our monthly round-up of new funds and the biggest job changes, including analysts, bankers, and healthcare journalists.
